Logo image of ATHE

ALTERITY THERAPEUTICS-ADR (ATHE) Stock Fundamental Analysis

USA - NASDAQ:ATHE - US02155X2053 - ADR

4.43 USD
-0.03 (-0.67%)
Last: 9/24/2025, 11:39:02 AM
Fundamental Rating

4

Overall ATHE gets a fundamental rating of 4 out of 10. We evaluated ATHE against 538 industry peers in the Biotechnology industry. ATHE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATHE is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATHE had negative earnings in the past year.
In the past year ATHE has reported a negative cash flow from operations.
ATHE had negative earnings in each of the past 5 years.
ATHE had a negative operating cash flow in each of the past 5 years.
ATHE Yearly Net Income VS EBIT VS OCF VS FCFATHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -26.39%, ATHE is in the better half of the industry, outperforming 71.38% of the companies in the same industry.
ATHE's Return On Equity of -28.65% is fine compared to the rest of the industry. ATHE outperforms 78.07% of its industry peers.
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHE Yearly ROA, ROE, ROICATHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

ATHE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHE Yearly Profit, Operating, Gross MarginsATHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K

More info and screens

6

2. Health

2.1 Basic Checks

ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ATHE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATHE Yearly Shares OutstandingATHE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M
ATHE Yearly Total Debt VS Total AssetsATHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

ATHE has an Altman-Z score of 9.94. This indicates that ATHE is financially healthy and has little risk of bankruptcy at the moment.
ATHE has a better Altman-Z score (9.94) than 84.76% of its industry peers.
ATHE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ATHE (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.94
ROIC/WACCN/A
WACC9.99%
ATHE Yearly LT Debt VS Equity VS FCFATHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M 30M

2.3 Liquidity

ATHE has a Current Ratio of 12.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
ATHE's Current ratio of 12.98 is amongst the best of the industry. ATHE outperforms 86.62% of its industry peers.
ATHE has a Quick Ratio of 12.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.98, ATHE belongs to the top of the industry, outperforming 86.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.98
Quick Ratio 12.98
ATHE Yearly Current Assets VS Current LiabilitesATHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

8

3. Growth

3.1 Past

ATHE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.62%, which is quite impressive.
ATHE shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.28%.
The Revenue has been growing by 92.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%

3.2 Future

ATHE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.
The Revenue is expected to grow by 225.69% on average over the next years. This is a very strong growth
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year1289.12%
Revenue Next 2Y261.01%
Revenue Next 3Y408.98%
Revenue Next 5Y225.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ATHE Yearly Revenue VS EstimatesATHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 2031 2032 200M 400M 600M 800M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATHE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHE Price Earnings VS Forward Price EarningsATHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHE Per share dataATHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ATHE's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATHE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTERITY THERAPEUTICS-ADR

NASDAQ:ATHE (9/24/2025, 11:39:02 AM)

4.43

-0.03 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2025-08-29
Earnings (Next)02-26 2026-02-26
Inst Owners13.83%
Inst Owner Change-8.22%
Ins Owners2.85%
Ins Owner ChangeN/A
Market Cap65.58M
Analysts100
Price TargetN/A
Short Float %0.65%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 222.46
P/FCF N/A
P/OCF N/A
P/B 2.34
P/tB 2.34
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.02
BVpS1.89
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.39%
ROE -28.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.98
Quick Ratio 12.98
Altman-Z 9.94
F-Score5
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)15.55%
Cap/Sales(5y)732.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
EPS Next Y100%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%
Revenue Next Year1289.12%
Revenue Next 2Y261.01%
Revenue Next 3Y408.98%
Revenue Next 5Y225.69%
EBIT growth 1Y26.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-118.6%
EBIT Next 3Y117.36%
EBIT Next 5YN/A
FCF growth 1Y9.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.16%
OCF growth 3YN/A
OCF growth 5YN/A